Furthermore, reliable and accurate information regarding IDH mutational status before or during surgery can help target glioma in surgical scenarios with genotype-specific local treatment against IDH, avoiding systemic toxicity [31]. This evidence concerns the gene IDH2 and central nervous system cancer.